Comprehensive Guide to Current and Upcoming Hormone-Based Weight Loss Drugs Including GLP-1 Agonists and Beyond
A comprehensive review of hormone-based anti-obesity medications finds that dual and triple receptor agonists (tirzepatide, retatrutide) can achieve up to 22% weight loss, far exceeding single-target GLP-1 drugs.
Quick Facts
What This Study Found
The evolution from single-target GLP-1 drugs to dual and triple receptor agonists is producing dramatically greater weight loss: tirzepatide (GIP/GLP-1) achieves 17.8% and retatrutide (GLP-1/GCG/GIP tri-agonist) achieves 22.1% placebo-subtracted weight reduction.
Key Numbers
Two GLP-1RAs are frontrunners. Triple agonists like retatrutide represent the next wave.
How They Did This
Narrative review of approved and emerging hormone-based anti-obesity medications, covering published clinical trial data for GLP-1RAs, dual and triple agonists, and amylin receptor agonists.
Why This Research Matters
Obesity affects over a billion people globally. The rapid advancement from single-target to multi-target hormone therapies is producing progressively greater weight loss, potentially approaching the efficacy of bariatric surgery with a medication-only approach.
The Bigger Picture
The obesity treatment landscape is undergoing a revolution driven by peptide-based therapeutics. Each generation of drugs achieves greater weight loss by targeting additional gut-brain hormone pathways. The long-term safety and cardiovascular benefits of newer agents remain to be established, but the trajectory suggests obesity may become a highly treatable condition.
What This Study Doesn't Tell Us
Review article — no new data generated. Long-term safety data for newer agents (tirzepatide, retatrutide) is limited. Cardiovascular outcome data is available primarily for semaglutide. Cost and access remain significant barriers to widespread use.
Questions This Raises
- ?Will triple agonists like retatrutide maintain their dramatic weight loss efficacy in larger phase III trials?
- ?What are the long-term cardiovascular and safety profiles of dual and triple receptor agonists?
- ?How will the availability of oral GLP-1 drugs change prescribing patterns and patient access?
Trust & Context
- Key Stat:
- 22.1% weight loss Achieved by retatrutide (GLP-1/GCG/GIP tri-agonist) in 48 weeks — the most effective hormone-based anti-obesity drug reported to date
- Evidence Grade:
- Review of mixed evidence strength — strong for approved drugs (liraglutide, semaglutide), moderate for tirzepatide, and preliminary for pipeline agents (retatrutide, oral GLP-1 drugs).
- Study Age:
- Published in 2024. Captures the state of the rapidly evolving obesity drug landscape.
- Original Title:
- Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.
- Published In:
- Indian journal of endocrinology and metabolism, 28(5), 445-460 (2024)
- Authors:
- Sidrak, Wael R, Kalra, Sanjay(3), Kalhan, Atul
- Database ID:
- RPEP-09265
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are the most effective weight loss drugs available now?
Currently approved hormone-based options include injectable semaglutide (~15% weight loss) and tirzepatide (~17.8% weight loss). Liraglutide is also available but less effective. Several more potent options, including oral GLP-1 drugs and triple agonists, are in clinical trials.
What is retatrutide and when might it be available?
Retatrutide is a triple agonist that targets GLP-1, glucagon, and GIP receptors simultaneously, achieving up to 22.1% weight loss in a phase II trial. It's still in clinical development and likely several years from potential approval.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09265APA
Sidrak, Wael R; Kalra, Sanjay; Kalhan, Atul. (2024). Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.. Indian journal of endocrinology and metabolism, 28(5), 445-460. https://doi.org/10.4103/ijem.ijem_442_23
MLA
Sidrak, Wael R, et al. "Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.." Indian journal of endocrinology and metabolism, 2024. https://doi.org/10.4103/ijem.ijem_442_23
RethinkPeptides
RethinkPeptides Research Database. "Approved and Emerging Hormone-Based Anti-Obesity Medications..." RPEP-09265. Retrieved from https://rethinkpeptides.com/research/sidrak-2024-approved-and-emerging-hormonebased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.